These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 22178195

  • 1. Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
    Seavey MM, Lu LD, Stump KL, Wallace NH, Ruggeri BA.
    Int Immunopharmacol; 2012 Jan; 12(1):257-70. PubMed ID: 22178195
    [Abstract] [Full Text] [Related]

  • 2. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.
    J Immunol; 2011 Oct 01; 187(7):3840-53. PubMed ID: 21880982
    [Abstract] [Full Text] [Related]

  • 3. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

  • 4. Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.
    Ikeda T, Fujii H, Nose M, Kamogawa Y, Shirai T, Shirota Y, Ishii T, Harigae H.
    Arthritis Res Ther; 2017 Aug 11; 19(1):187. PubMed ID: 28800777
    [Abstract] [Full Text] [Related]

  • 5. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma.
    Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C.
    Leuk Lymphoma; 2017 Aug 11; 58(8):1872-1879. PubMed ID: 28140719
    [Abstract] [Full Text] [Related]

  • 6. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR, Leestemaker Y, Schuurman KG, Ruggeri B, Jones-Bolin S, Williams M, Ovaa H.
    Mol Pharm; 2012 May 07; 9(5):1126-35. PubMed ID: 22432738
    [Abstract] [Full Text] [Related]

  • 7. The beneficial effects of treatment with all-trans-retinoic acid plus corticosteroid on autoimmune nephritis in NZB/WF mice.
    Nozaki Y, Yamagata T, Yoo BS, Sugiyama M, Ikoma S, Kinoshita K, Funauchi M, Kanamaru A.
    Clin Exp Immunol; 2005 Jan 07; 139(1):74-83. PubMed ID: 15606616
    [Abstract] [Full Text] [Related]

  • 8. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
    Okazaki H, Hirata D, Kamimura T, Sato H, Iwamoto M, Yoshio T, Masuyama J, Fujimura A, Kobayashi E, Kano S, Minota S.
    J Rheumatol; 2002 Apr 07; 29(4):707-16. PubMed ID: 11950011
    [Abstract] [Full Text] [Related]

  • 9. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.
    Alexander T, Sarfert R, Klotsche J, Kühl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE.
    Ann Rheum Dis; 2015 Jul 07; 74(7):1474-8. PubMed ID: 25710470
    [Abstract] [Full Text] [Related]

  • 10. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
    Sanchez E, Li M, Li J, Wang C, Chen H, Jones-Bolin S, Hunter K, Ruggeri B, Berenson JR.
    Leuk Res; 2012 Nov 07; 36(11):1422-7. PubMed ID: 22906694
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of PI3Kδ reduces kidney infiltration by macrophages and ameliorates systemic lupus in the mouse.
    Suárez-Fueyo A, Rojas JM, Cariaga AE, García E, Steiner BH, Barber DF, Puri KD, Carrera AC.
    J Immunol; 2014 Jul 15; 193(2):544-54. PubMed ID: 24935930
    [Abstract] [Full Text] [Related]

  • 12. Effect of combining ACE inhibitor and statin in lupus-prone mice.
    Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M.
    Clin Immunol; 2010 Aug 15; 136(2):188-96. PubMed ID: 20403731
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice].
    Ding ZX, Yang SF, Wu QF, Lu Y, Chen YY, Nie XL, Jie HY, Qi JM, Wang FS.
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Apr 15; 31(4):656-60. PubMed ID: 21515463
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B, Schmidt RE, Witte T.
    Arthritis Rheum; 2005 Nov 15; 52(11):3629-38. PubMed ID: 16255055
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice.
    Jonsson CA, Svensson L, Carlsten H.
    Clin Exp Immunol; 1999 Jun 15; 116(3):534-41. PubMed ID: 10361247
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.